Gastrointestinal

Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
(Merck) MK-3475-966Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with advanced/Unresectable Biliary Tract CarcinomaKazemi, Dr GhazalehOpen to recruitmentNCT04003636
(AstraZeneca) D933GC00001 / EMERALD-1A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular CarcinomaZbuk, Dr KevinRecruitment on hold - COVID-19NCT03778957
(CCTG) CO.21 / CHALLENGEA Phase III Study of the Impact of a Physical Activity Program on Disease-Free Survival in Patients With High Risk Stage II or Stage III Colon Cancer: A Randomized Controlled Trial (CHALLENGE)Goffin, Dr JohnRecruitment on hold - COVID-19NCT00819208
(EXELIXIS) XL184-312 / COSMIC-312A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer TherapyMeyers, Dr BrandonRecruitment on hold - COVID-19NCT03755791
(H3 Biomedicine and Eisai) H3B-6527-G000-101An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular CarcinomaMeyers, Dr BrandonRecruitment on hold - COVID-19NCT02834780
(UHN) OZM-067 / LuNETA Prospective Single-Arm, Multi-Centre, Study of the Efficacy and Safety of Lutetium-177 Octreotate (Lu-DOTATATE) Treatment with individualized dosimetry in Patients with 68Ga-DOTATATE identified Somatostatin Receptor positive Neuroendocrine TumorsJuergens, Dr RosalynRecruitment on hold - COVID-19NCT02743741
RTOG 1112Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular CarcinomaSwaminath, Dr AnandRecruitment on hold - COVID-19NCT01730937
Download PDF